

WEDNESDAY, 29th APRIL 2009 COMMENCING 10.30 AM
(UNTIL 4.30 PM APPROX)
AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN

AGENDA

- | | | Enclosure |
|-----|---|---|
| 1. | Welcome and introduction | |
| 2. | Apologies | |
| 3. | Declarations of interest | |
| 4. | Chairman's report (verbal update) | |
| 5. | Minutes of previous meeting
- Matters arising | 1/AWMSG/0209 |
| 11. | Appraisal 1 (in light of independent review)
Ambrisentan (Volibris [®]) for the treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO functional Class II and III, to improve exercise capacity, decrease the symptoms of PAH and delay clinical worsening | 7/AWMSG/0209
Appendices

Agenda item moved |
| 6. | Appraisal 2:
Aliskiren (Rasilez [®] ▼) for the treatment of essential hypertension
This appraisal is postponed | 2/AWMSG/0209
Appendices |
| 7. | Appraisal 3:
Eculizumab (Soliris [®] ▼) for the treatment of paroxysmal nocturnal haemoglobinuria | 3/AWMSG/0209
Appendices |
| 8. | Appraisal 4:
Maraviroc (Celsentri [®] ▼) for the treatment-experienced adults infected only with CCR5-tropic HIV-1 | 4/AWMSG/0209
Appendices |
| 9. | Appraisal 5:
Anidulafungin (Ecalta [®] ▼) for the treatment of invasive candidiasis in adult non-neutropenic patients | 5/AWMSG/0209
Appendices |
| 10. | Appraisal 6:
Nelarabine (Atriance [®] ▼) for the treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma | 6/AWMSG/0209
Appendices |
| 12. | Update on AWPAG
Terminology for shared care, near patient testing and enhanced services - subcutaneous methotrexate | 8/AWMSG/0209 |
| 13. | Date of next meeting: Wednesday, 24th June 2009 | |